![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-190705-biontech-logo-rgb-dark-green-preferred-0.png\"){kind=logo}
<\/p>\n<\/p>\n
Pfizer Inc. announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine development program against COVID-19. The EMA’s decision to start a rolling review follows the encouraging preliminary results from pre-clinical and early clinical studies in adults, which suggest that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2. A combination of an antibody and T cell response is believed to be important in eliciting protection against viral infection and disease. BioNTech and Pfizer plan to work with the EMA’s Committee for Medicinal Products for Human Use (CHMP) to complete the rolling review process to facilitate the final Marketing Authorization Application (MAA).<\/p>\n
As part of the rolling review, the CHMP has begun evaluating data generated in pre-clinical trials. The formal MAA submission could be finalized following the rolling review process, pending demonstration of vaccine efficacy and safety and confirmation from the EMA that the submitted data are adequate. The vaccine candidate will remain subject to the EMA’s diligent standards for quality, safety and efficacy.<\/p>\n
“It is our duty to ensure that while we are working to develop a potential vaccine at unprecedented speed to help address this pandemic, we do so with the highest ethical standards while adhering to sound scientific principles. We will continue to have regular and open dialogue with the EMA throughout the rolling review process,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.<\/strong><\/p>\n “A global crisis the magnitude of COVID-19 has completely transformed the vaccine development and review process,” said Peter Honig, M.D., Senior Vice President and Head of Worldwide Safety and Regulatory of Pfizer<\/strong>. “We are making every effort to develop a safe and effective vaccine following the guidance of regulatory agencies and are proud to take this historic step with the European Medicines Agency for our COVID-19 vaccine candidate, BNT162b2.”<\/p>\n The BNT162b2 vaccine candidate is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. It encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), which is a target of virus neutralizing antibodies. The vaccine candidate is currently being evaluated in a global Phase 3 study ongoing at more than 120 clinical sites worldwide including the United States, Brazil, South Africa and Argentina. To date, the trial has enrolled approximately 37,000 participants with more than 28,000 having received their second vaccination.<\/p>\n Preliminary data from the Phase 1\/2 portions of the study have demonstrated that BNT162b2 was well tolerated with mild to moderate adverse events in all age groups. The vaccine candidate generated dose level-dependent immunogenicity, as measured by receptor binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 neutralizing titers. In addition, BNT162b2-vaccinated human participants displayed a favorable breadth of epitopes recognized in T cell responses specific to the SARS-CoV-2 spike antigen, and BNT162b2 demonstrated a concurrent induction of high magnitude CD4+ and CD8+ T cell responses which were TH-1 dominant against the RBD and the remainder of the full spike glycoprotein. Full information on previously released data can be found here. For further information about the ongoing Phase 3 trial, visit www.ClinicalTrials.gov using the number NCT04368728.<\/p>\n About the EMA’s Rolling Review<\/strong><\/p>\n Normally, all data on an investigational medicine’s efficacy, safety and quality and all required documents must be submitted at the start of the evaluation in a complete application for marketing authorization. In the case of a rolling review, the EMA’s CHMP reviews data as they become available from ongoing studies, before a complete application is submitted. Once the CHMP decides that sufficient data are available, the complete application should be submitted by the company. By reviewing the data as they become available, the CHMP can reach its opinion sooner on whether or not the investigational medicine or vaccine should be authorized. After a positive opinion, if adopted by the CHMP, it is the European Commission’s role to grant a Marketing Authorization.<\/p>\n About Pfizer: Breakthroughs That Change Patients’ Lives<\/strong><\/p>\n At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com<\/p>\n Pfizer Contacts:<\/strong><\/p>\n Media Relations<\/strong> Investor Relations<\/strong> BioNTech Contacts:<\/strong><\/p>\n Media Relations<\/strong> Investor Relations<\/strong> <\/p>\n Tags:<\/b> Sylke Maas, Ph.D.
Andy Widger
+44 7970 149098
andrew.widger@pfizer.com<\/p>\n
Chuck Triano
+1 (212) 733-3901
Charles.E.Triano@Pfizer.com<\/p>\n
Jasmina Alatovic
+49 (0)6131 9084 1513 or +49 (0)151 1978 1385
Media@biontech.de<\/p>\n
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de<\/p>\nSee Campaign: <\/strong>http:\/\/biontech.de<\/a>
Contact Information:<\/b>
Sylke Maas, Ph.D.
\n+49 (0)6131 9084 1074
\nInvestors@biontech.de<\/p>\n
<\/a>, Wire<\/a>, Disclosure Newswire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
\n+49 (0)6131 9084 1074
\nInvestors@biontech.de<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":" Pfizer Inc. announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine development program against COVID-19. The EMA’s decision to start a rolling review follows the encouraging preliminary results from pre-clinical and early clinical studies in adults, which suggest that BNT162b2 triggers the production of … Continue reading BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2<\/span><\/a> Continue Reading